Home Institutions NYU Langone Health clinical trials Institution Directory
Clinical trials at NYU Langone Health Sites in New York, NY
Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.
ClinicalTrials.gov public records Last synced Oct 19, 2026, 12:01 PM EDT
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
1136
Current sort
Recently updated
Campus scope
NYU Langone Health, New York, NY
Additional filters apply within this campus.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 121–132 of 1,136 matching trials with a site at NYU Langone Health, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.
Live official records
Conditions Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions Tirzepatide, Retatrutide, Placebo Drug
Lead sponsor Eli Lilly and Company Industry
Eligibility 18 Years and older
Enrollment 4,500 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2032
U.S. locations 141
States / cities Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more
Conditions Oropharyngeal Carcinoma (OPC)
Interventions CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel Drug
Lead sponsor Corbus Pharmaceuticals Inc. Industry
Eligibility 18 Years and older
Enrollment 260 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 38
States / cities Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more
Conditions Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis
Interventions Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD), MIRV, Bevacizumab, Carboplatin Drug
Lead sponsor Eli Lilly and Company Industry
Eligibility 18 Years and older
Enrollment 1,630 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2031
U.S. locations 86
States / cities Birmingham, Alabama • Phoenix, Arizona • Burbank, California + 68 more
Conditions Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Interventions Retatrutide, Placebo Drug
Lead sponsor Eli Lilly and Company Industry
Eligibility 45 Years and older
Enrollment 10,000 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2024 – 2029
U.S. locations 204
States / cities Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
Conditions Migraine
Interventions RELAXaHEAD Smartphone App Version 1, RELAXaHEAD Smartphone App Version 2 Behavioral
Lead sponsor NYU Langone Health Other
Eligibility 16 Years to 80 Years
Enrollment 450 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2028
U.S. locations 1
States / cities New York, New York
Conditions Ventricular Arrhythmia, Tachycardia
Interventions Defibrillation using EV-ICD Device
Lead sponsor Medtronic Industry
Eligibility Not listed
Enrollment 1,000 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2023 – 2037
U.S. locations 57
States / cities Huntington Park, California • Redwood City, California • San Diego, California + 45 more
Conditions Lymphoma, Large B-Cell, Diffuse
Interventions Zilovertamab vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Rituximab Biosimilar, Prednisone, Prednisolone, Polatuzumab vedotin, Rescue Medication Biological · Drug
Lead sponsor Merck Sharp & Dohme LLC Industry
Eligibility 18 Years and older
Enrollment 594 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2032
U.S. locations 73
States / cities Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 64 more
Conditions Diabetic Macular Edema
Interventions PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange Drug
Lead sponsor Hoffmann-La Roche Industry
Eligibility 18 Years and older
Enrollment 672 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2019 – 2027
U.S. locations 89
States / cities Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more
Conditions NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Interventions Satralizumab, Placebo Drug · Other
Lead sponsor Hoffmann-La Roche Industry
Eligibility 12 Years and older
Enrollment 122 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2028
U.S. locations 11
States / cities Birmingham, Alabama • Newport Beach, California • San Francisco, California + 7 more
Conditions Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, B-cell Marginal Zone, Waldenstrom Macroglobulinemia, Lymphoma, Mantle Cell
Interventions LY4152199 - IV Drug
Lead sponsor Eli Lilly and Company Industry
Eligibility 18 Years and older
Enrollment 215 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2026 – 2029
U.S. locations 23
States / cities Duarte, California • Aurora, Colorado • Denver, Colorado + 17 more
Conditions Nausea, Vomiting, Drug-Related Side Effects and Adverse Reactions, Neoplasms
Interventions LY3537021, Placebo, Standard of Care Antiemetic Therapies, Background Chemotherapy Drug
Lead sponsor Eli Lilly and Company Industry
Eligibility 18 Years and older
Enrollment 204 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2025 – 2027
U.S. locations 20
States / cities Greenbrae, California • Irvine, California • Los Alamitos, California + 17 more
Conditions Obesity, Overweight
Interventions Tirzepatide, Placebo Drug
Lead sponsor Eli Lilly and Company Industry
Eligibility 40 Years and older
Enrollment 15,374 participants
Healthy volunteers Healthy volunteers not accepted
Timeline 2022 – 2027
U.S. locations 165
States / cities Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 141 more About this NYU Langone Health institution page
What this page lists ClinicalTrials.gov records that list NYU Langone Health in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.
Related: all institution pages , browse by condition , or browse by U.S. city .